ACAD
32.82
+0.52
+1.61%
AEMD
5.3
-0.05
-0.93%
APRI
0.348
+0.008
+2.2614%
ARNA
1.61
-0.02
-1.2331%
ATEC
3.692
+0.092
+2.556%
CNAT
1.91
-0.03
-1.55%
CRXM
0.168
0.00
0.00%
CYTX
2.03
0.00
0.00%
DXCM
91.1
+0.48
+0.53%
GNMK
8.8
+0.06
+0.69%
HALO
9.71
+0.16
+1.68%
ILMN
172.265
+2.785
+1.643%
INNV
0.281
-0.119
-29.750%
INO
8.8
+0.13
+1.50%
ISCO
1.95
0.00
0.00%
ISIS
57.56
0.00
0.00%
LGND
103.34
-0.31
-0.30%
LPTN
2.739
-0.081
-2.872%
MBVX
5.01
-0.08
-1.52%
MEIP
1.93
-0.05
-2.53%
MNOV
6.16
-0.26
-4.05%
MRTX
5.09
+0.11
+2.21%
MSTX
0.4
0.00
+1.04%
NBIX
49.5
+0.56
+1.14%
NUVA
63.89
+0.5
+0.79%
ONCS
1.689
-0.032
-1.8314%
ONVO
3.885
-0.015
-0.385%
OREX
3.86
+0.04
+1.05%
OTIC
16.08
+0.4
+2.55%
QDEL
21.59
+0.17
+0.79%
RCPT
231.96
0.00
0.00%
RGLS
3.23
+0.07
+2.22%
RMD
69.024
+0.584
+0.8526%
SPHS
3.53
+0.03
+0.86%
SRNE
6.59
+0.03
+0.46%
TROV
5.02
+0.1
+2.03%
VICL
3.91
+0.06
+1.56%
VOLC
18
0.00
0.00%
ZGNX
9.3
+0.22
+2.42%
ACAD
32.82
+0.52
+1.61%
AEMD
5.3
-0.05
-0.93%
APRI
0.348
+0.008
+2.2614%
ARNA
1.61
-0.02
-1.2331%
ATEC
3.692
+0.092
+2.556%
CNAT
1.91
-0.03
-1.55%
CRXM
0.168
0.00
0.00%
CYTX
2.03
0.00
0.00%
DXCM
91.1
+0.48
+0.53%
GNMK
8.8
+0.06
+0.69%
HALO
9.71
+0.16
+1.68%
ILMN
172.265
+2.785
+1.643%
INNV
0.281
-0.119
-29.750%
INO
8.8
+0.13
+1.50%
ISCO
1.95
0.00
0.00%
ISIS
57.56
0.00
0.00%
LGND
103.34
-0.31
-0.30%
LPTN
2.739
-0.081
-2.872%
MBVX
5.01
-0.08
-1.52%
MEIP
1.93
-0.05
-2.53%
MNOV
6.16
-0.26
-4.05%
MRTX
5.09
+0.11
+2.21%
MSTX
0.4
0.00
+1.04%
NBIX
49.5
+0.56
+1.14%
NUVA
63.89
+0.5
+0.79%
ONCS
1.689
-0.032
-1.8314%
ONVO
3.885
-0.015
-0.385%
OREX
3.86
+0.04
+1.05%
OTIC
16.08
+0.4
+2.55%
QDEL
21.59
+0.17
+0.79%
RCPT
231.96
0.00
0.00%
RGLS
3.23
+0.07
+2.22%
RMD
69.024
+0.584
+0.8526%
SPHS
3.53
+0.03
+0.86%
SRNE
6.59
+0.03
+0.46%
TROV
5.02
+0.1
+2.03%
VICL
3.91
+0.06
+1.56%
VOLC
18
0.00
0.00%
ZGNX
9.3
+0.22
+2.42%
Home » Archive by Category

Xconomy

Biotech Roundup: Kadmon Debt, Hemo Data, Loose Lips & More

June 17, 2016 – 3:30 am

Familiar biotech names—not necessarily familiar for the right reasons—made news this week in biotech. Data from a hematology conference stoked dreams of approval, though still on a far…

[[Click headline to continue reading.]]

Biotech Roundup: ASCO, BIO, Drug Setbacks, Incubators & More

June 10, 2016 – 3:30 am

If you blinked, you probably missed something this week in biotech. The nation’s biggest annual cancer meeting took place in Chicago, while biotech’s trade group held its annual confab in San…

[[Click headline to continue reading.]]

How to Make Healthcare Better? Make It Easy

June 8, 2016 – 5:59 am

There’s an “easy button” in the hospital that I press a hundred times every day. With each press, I make myself a better doctor. It’s not a button on a computer. It’s not electronic at all. It’s a…

[[Click headline to continue reading.]]

Biotech Roundup: Deals Gone Wrong, Ethical Red Flags & Bay Goodbyes

June 3, 2016 – 3:30 am

It was fitting this week that, in the lead-up to two of biomedicine’s biggest self-celebrations, we were served ample reminder of the industry’s expensive decisions gone wrong. This…

[[Click headline to continue reading.]]

Two Years After Paying $680M, BioMarin Shelves Duchenne Drug

May 31, 2016 – 2:44 pm

BioMarin Pharmaceutical took a $680 million gamble when it bought Prosensa in 2014 for its experimental Duchenne muscular dystrophy treatment. Drisapersen (Kydrisa) had already failed a Phase 3…

[[Click headline to continue reading.]]

With Recruits Coming, Precision Med Effort Pledges $142M For Biobank

May 27, 2016 – 11:56 am

The Obama administration’s ambitious long-term health study, dubbed the Precision Medicine Initiative, has tapped the Mayo Clinic to build a repository for biological samples collected from the…

[[Click headline to continue reading.]]

Biotech Roundup: Duchenne Delay, Forum’s Fate, Califf, Ionis & More

May 27, 2016 – 5:40 am

Memorial Day weekend may be fast approaching, but don’t fire up those grills yet: there’s plenty of headlines to dig into first in our biotech trip around the Xconomy network. In New York, the…

[[Click headline to continue reading.]]

FDA Commish Califf to Big Data Crowd: Flood Of New Treatments Coming

May 26, 2016 – 1:31 pm

New FDA commissioner Robert Califf said Wednesday that the recent spike in drug approvals is no temporary phenomenon, thanks to a better understanding of biology and continued adoption of…

[[Click headline to continue reading.]]

Sophiris Streamlines Operations, Weighs Options on Prostate Drug

May 24, 2016 – 11:53 pm

[Updated 5/25/16 2:35 pm with analyst comments. See below.] After advancing its experimental prostate drug to late-stage clinical trials, San Diego-based Sophiris Bio (NASDAQ: SPHS) has been…

[[Click headline to continue reading.]]

The Biotech Roundup: Immunotherapy Ups And Downs, Gene Deals & More

May 20, 2016 – 3:30 am

A quick housekeeping note: Starting this week, we are combining our East Coast and West Coast biotech roundups into a single weekly post that will also include highlights from our other cities and…

[[Click headline to continue reading.]]